Early progression as a predictor of survival in marginal zone lymphomas: An analysis from the FIL-NF10 study

S. Luminari, M. Merli, S. Rattotti, V. Tarantino, L. Marcheselli, F. Cavallo, M. Varettoni, B. Bianchi, F. Merli, A. Tedeschi, G. Cabras, F. Re, C. Visco, M.T. Delamain, E. Cencini, M. Spina, S. Ferrero, A. Ferrari, M. Deodato, D. ManninaO. Annibali, A. Rago, L. Orsucci, I. Defrancesco, M. Frigeni, M. Cesaretti, L. Arcaini

Research output: Contribution to journalArticlepeer-review


Marginal zone lymphomas (MZLs) are indolent nonfollicular B-cell lymphomas (INFLs) and have heterogeneous clinical behavior. Recently, time to progression of disease at 24 months (POD24) was identified to stratify overall survival (OS) in follicular non-Hodgkin lymphoma and in INFL. Here, we examined the ability of POD24 to predict subsequent OS in a large, international cohort of MZL as part of the NF10 prospective international registry headed by Fondazione Italiana Linfomi (FIL). POD24 was only calculated for MZL patients requiring immediate therapy and was defined as experiencing lymphoma progression within 24 months from diagnosis. Among the 1325 patients enrolled in the NF10 study, we identified 321 patients with MZL for whom immediate therapy was planned right after lymphoma diagnosis. Overall, POD24 was confirmed in 59 patients (18%). Three-year OS for patients with POD24 was 53% with a hazard ratio of 19.5 (95% confidence interval, 8.4-45) compared with patients without POD24 (3-year OS, 95%). Association of POD24 with OS was confirmed for the subgroup of splenic and extranodal MZLs. Assessment of POD24 stratifies subsequent outcome inMZL and identifies a high-risk population. © 2019 by The American Society of Hematology.
Original languageEnglish
Pages (from-to)798-801
Number of pages4
Issue number10
Publication statusPublished - Sept 5 2019


  • albumin
  • bendamustine
  • beta 2 microglobulin
  • cyclophosphamide plus doxorubicin plus prednisolone plus rituximab plus vincristine
  • fludarabine
  • hemoglobin
  • lactate dehydrogenase
  • adult
  • albumin blood level
  • Article
  • autologous stem cell transplantation
  • cancer chemotherapy
  • cancer immunotherapy
  • cancer radiotherapy
  • cause of death
  • cause specific survival
  • cohort analysis
  • disease duration
  • disease exacerbation
  • Follicular Lymphoma International Prognostic Index
  • follow up
  • hemoglobin blood level
  • high risk population
  • human
  • immunochemotherapy
  • lactate dehydrogenase blood level
  • lymphocyte count
  • major clinical study
  • marginal zone lymphoma
  • middle aged
  • observational study
  • overall survival
  • platelet count
  • priority journal
  • prospective study
  • survival analysis
  • systemic therapy
  • aged
  • female
  • male
  • mortality
  • pathology
  • prognosis
  • time factor
  • very elderly
  • Adult
  • Aged
  • Aged, 80 and over
  • Disease Progression
  • Female
  • Humans
  • Lymphoma, B-Cell, Marginal Zone
  • Male
  • Middle Aged
  • Prognosis
  • Prospective Studies
  • Survival Analysis
  • Time Factors


Dive into the research topics of 'Early progression as a predictor of survival in marginal zone lymphomas: An analysis from the FIL-NF10 study'. Together they form a unique fingerprint.

Cite this